News | October 25, 2011

European Journal Features Results of Self-Apposing Stent Study


October 25, 2011 — Stentys S.A. announced the publication of the results of the APPOSITION I clinical study in the September issue of the medical journal EuroIntervention.

The study showed the Stentys Self-Apposing Stent enabled the perfect apposition of these stents when treating patients with acute myocardial infarction (AMI). The self-apposing feature ensures optimal apposition during thrombus and vessel spasm relief in the critical initial hours and days after an AMI procedure; this avoids malapposition, a significant concern to cardiologists.

“We continue to be very pleased with the results of the Stentys Self-Apposing Stent when treating AMI,” said Giovanni Amoroso, M.D., OLVG Hospital (Amsterdam, the Netherlands) and lead author of the article. “During the six-month follow-up period of the APPOSITION I study, there was no death, no stent thrombosis or reoccurrence of MI, with revascularization rates comparable to that of conventional stents.”

EuroIntervention is the official publication of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI); it is endorsed by the European Society of Cardiology (ESC).

For more information: www.eurointervention.org


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now